Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
|Videos|March 23, 2021
Psychedelic Wellness
Author(s)Matt Stang
Early studies find psilocybin shows promise for some psychiatric disorders...
Advertisement
With numerous studies in stage 3 trials, the opportunities to leverage psilocybin for clinical care is likely to expand in the next few years. Matt Stang shares his excitement for the future of this agent as means to help more patients.
To learn more on psilocybin and earn CME credit, see
Mr Stang is the founder of
Advertisement
Related to this article
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Dementia and the Tuberculosis Vaccine: Reduced Tau Burden With Administration in Mice
2
GLP-1 Receptor Agonists May Reinforce Restriction in Patients With Eating Disorders
3
ALKS 7290 for Adjunctive Treatment for MDD Enters Phase 2 Study
4
October 2026 in Review: Updates on the Psychiatric Treatment Pipeline, FDA News
5